OPKO Health (NASDAQ:OPK) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of OPKO Health (NASDAQ:OPK) from a hold rating to a sell rating in a report published on Saturday morning.

Several other research firms have also recently commented on OPK. JPMorgan Chase & Co. started coverage on OPKO Health in a research report on Thursday, November 20th. They set a “neutral” rating for the company. Barrington Research dropped their price target on OPKO Health from $2.25 to $1.50 and set an “outperform” rating for the company in a research report on Monday, March 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, OPKO Health has an average rating of “Hold” and an average target price of $2.03.

OPKO Health Trading Up 0.9%

OPKO Health stock opened at $1.18 on Friday. The stock has a market cap of $895.70 million, a P/E ratio of -3.93 and a beta of 1.50. OPKO Health has a fifty-two week low of $1.11 and a fifty-two week high of $1.95. The firm’s fifty day moving average price is $1.26 and its 200-day moving average price is $1.35. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.32 and a current ratio of 3.97.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. The company had revenue of $148.50 million for the quarter, compared to the consensus estimate of $139.76 million. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.The firm’s revenue was down 19.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.01 earnings per share. Equities research analysts forecast that OPKO Health will post -0.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its holdings in shares of OPKO Health by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 11,061,318 shares of the biotechnology company’s stock worth $13,940,000 after purchasing an additional 67,973 shares in the last quarter. Millennium Management LLC raised its holdings in shares of OPKO Health by 39.2% during the 1st quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock valued at $10,602,000 after buying an additional 1,798,385 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in OPKO Health by 150.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company’s stock worth $7,544,000 after buying an additional 3,600,378 shares during the last quarter. UBS Group AG lifted its position in OPKO Health by 12.1% in the 4th quarter. UBS Group AG now owns 5,352,784 shares of the biotechnology company’s stock worth $6,745,000 after buying an additional 577,248 shares during the last quarter. Finally, AWM Investment Company Inc. boosted its stake in OPKO Health by 8.1% in the second quarter. AWM Investment Company Inc. now owns 2,000,000 shares of the biotechnology company’s stock worth $2,640,000 after buying an additional 150,000 shares in the last quarter. Institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.